Cargando…
AHNAK2 is a biomarker and a potential therapeutic target of adenocarcinomas: AHNAK2 is a biomarker for adenocarcinomas
Adenocarcinoma is the second largest histological type of cervical cancer, second only to cervical squamous cell carcinoma. At present, despite the clinical treatment strategies of cervical adenocarcinoma and cervical squamous cell carcinoma being similar, the outcome and prognosis of cervical adeno...
Autores principales: | Xu, Meng, Cheng, Anyi, Yu, Liya, Wei, Wei, Li, Jinpeng, Cai, Cheguo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828698/ https://www.ncbi.nlm.nih.gov/pubmed/36017889 http://dx.doi.org/10.3724/abbs.2022112 |
Ejemplares similares
-
AHNAK2 is a potential prognostic biomarker in patients with PDAC
por: Lu, Di, et al.
Publicado: (2017) -
The Obscure Potential of AHNAK2
por: Zardab, Mohamed, et al.
Publicado: (2022) -
AHNAK2 Is Associated with Poor Prognosis and Cell Migration in Lung Adenocarcinoma
por: Zhang, Shusen, et al.
Publicado: (2020) -
AHNAKs roles in physiology and malignant tumors
por: Zhang, Shusen, et al.
Publicado: (2023) -
Downregulation of AHNAK2 inhibits cell cycle of lung adenocarcinoma cells by interacting with RUVBL1
por: Li, Xin, et al.
Publicado: (2023)